With the aim of ensuring local cancer control and minimising disease recurrence, the interventional science theme will deliver improvements in early detection and diagnosis, surgery, radiotherapy, novel localised therapies and innovations to monitor therapeutic efficacy.


The Centre's ambition is to support novel technologies bringing solutions to unmet needs along the patient journey. In early detection, we focus our efforts on bringing the continued development of ultrasensitive low-cost devices to detect specific early disease signals, supported by clinical positioning and adoption strategies. We plan to design interventional trials (e.g. targeted screening) to risk-stratified populations. We bring innovations to common intervention such as in surgery, which remains the most important curative option for most solid malignancies, to improve surgical precision through robotics, imaging and margin monitoring tools. As modern technologies' need for processing and analysis grow, we support a Data Science and Digital Pathology initiative to connect new devices for real-time analysis and smarter processing. We continue to develop techniques and technologies to improve strategies for local control of advanced-stage cancers. Through our Clinical Drug Development initiative, we expect to accelerate new drug and medical device approvals. To drive uptake and adoption of our innovations within the NHS, we wish to address the regulatory challenges associated with novel interventions. We provide expertise in Implementation Science, Human Factors and Health Economics. 









    If you have any questions relating to the Interventional Science theme please contact Chloe Stockford (chloe.stockford@imperial.ac.uk)